Patent US4228180A successfully refreshed from Google Patents.
US4228180A
Expired / Lapsed
US
⏱️ 0.0 years remaining
7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs
Assignee: ER Squibb and Sons LLC
•
Filing: 1979-11-01
•
Granted: 1980-10-14
•
Expires: 1999-11-01
Abstract
Abstract New 7-oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs which have the general formula ##STR1## wherein R 1 is hydrogen or lower alkyl; n is 0 to 4, m is 0 to 4 and x is 0 to 8, are useful as cardiovascular agents.
Inventors
- 👤 Peter W. Sprague
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 11:43
CPC Classifications
C; C07; C07D; C07D493/00; C07D493/02; C07D493/08; A; A61; A61P; A61P11/00; A61P11/08; A61P7/00; A61P7/02; A61P9/00; A61P9/08; A61P9/10
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
30 words
A compound of the formula ##STR48## wherein R 1 is hydrogen or lower alkyl; n is 0 to 4, m is 0 to 4 and x is 0 to 8.
Claim 2
Dependent Claim
30 words
A compound of the formula ##STR48## wherein R 1 is hydrogen or lower alkyl; n is 0 to 4, m is 0 to 4 and x is 0 to 8.
Claim 3
Dependent Claim
13 words
The compound of claim 1 wherein n is 1 and m is 3.
Claim 4
Dependent Claim
24 words
The compound of claim 2 wherein x is 0 and the lower alkyl attached to the olefinic carbon atom contains 4 to 6 carbons.
Claim 5
Dependent Claim
10 words
The compound of claim 1 wherein R 1 is methyl.
Claim 6
Dependent Claim
10 words
The compound of claim 1 having the name [1R-(1α,2β(5Z),3β(1E),4α)]-7-[3-(1-octenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Claim 7
Dependent Claim
10 words
The compound of claim 1 having the name [1R-(1α,2β(5Z),3β(1E),4α]-7-[3-(1-octenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Claim 8
Dependent Claim
38 words
A method of inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, which comprises administering to the circulatory system of a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
26 words
The method as defined in claim 7 wherein said compound is administered in an amount within the range of from about 1 to about 100 mg/kg.
Claim 10
Dependent Claim
34 words
A composition for inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, comprising an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.
Claim 11
Dependent Claim
30 words
A method of inhibiting platelet aggregation which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
32 words
A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US4112224A
Cited
US4143054A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-10-14 | 1984-04-14 | 1984-10-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-10-14 | 1988-04-14 | 1988-10-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-10-14 | 1992-04-14 | 1992-10-14 | $7700.00 | Window Closed / Lapsed |